FDA Warning Letters: Oct. 14
This article was originally published in The Gray Sheet
FDA posted three device warning letters on Oct. 14, including one to Zoll's Lifecor division, which makes the LifeVest wearable defibrillator, for quality systems and adverse-event reporting violations.
You may also be interested in...
At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.
Health technology assessment body NICE is consulting on draft guidance that recommends Axonics' device for overactive bladder.